APP Pharmaceuticals Announces Expanded Supply of Methotrexate Injection, USP

SCHAUMBURG, Ill.--(BUSINESS WIRE)--APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that in the past week it has released to the market 35,000 vials of Methotrexate Injection, USP. In addition, the Company has filled 10,000 vials of preservative-free Methotrexate Injection, USP, which should be available to clinicians within three weeks. A further 10,000 vials have been filled and will be shipped to customers by the end of March. Just two weeks ago, APP received approval from the FDA for preservative-free Methotrexate in order to help ease the ongoing shortage. APP produces both forms of Methotrexate Injection at its Melrose Park, Illinois manufacturing facility.